Anti-acne Efficacy of a Dermo-cosmetic Product Associated With the Fixed Combination Adapalene 0.1%/ Benzoyl Peroxide 2.5% Treatment Versus This Treatment Associated With a Standard Moisturizer in Male and Female Subjects Presenting With Mild to Moderate Acne

NCT ID: NCT03832647

Last Updated: 2021-10-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-02-18

Study Completion Date

2020-02-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study to evaluate the anti-acne efficacy of a dermo-cosmetic associated with the fixed combination Adapalene 0.1%/ benzoyl peroxide 2.5% treatment and to demonstrate that the dermo-cosmetic product can improve the local tolerance of the fixed combination Adapalene 0.1%/ benzoyl peroxide 2.5% treatment

Multi centre, Randomised, Double blind, Controlled, Parallel (100 subjects per arm), Intra-subject \& inter subject comparisons

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acne

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

100 subjects per arm
Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators
double blind

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hydréane légère & Epiduo 0.1%-2.5% Topical Gel

Hydréane légère: Once-a-day, on the morning, during 12 weeks.

Epiduo gel: Once-a-day, on the evening (before bedtime) during 12 weeks.

Group Type PLACEBO_COMPARATOR

Epiduo

Intervention Type COMBINATION_PRODUCT

100 per arm Adapalene/ Benzoyl Peroxide

Hydréane légère

Intervention Type OTHER

moisturizer

Salicylic acid & Epiduo 0.1%-2.5% Topical Gel

Salicylic acid: Once-a-day, on the morning, during 12 weeks.

Epiduo gel: Once-a-day, on the evening (before bedtime) during 12 weeks.

Group Type EXPERIMENTAL

Epiduo

Intervention Type COMBINATION_PRODUCT

100 per arm Adapalene/ Benzoyl Peroxide

Salicylic Acid

Intervention Type DRUG

Salicylic Acid

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Epiduo

100 per arm Adapalene/ Benzoyl Peroxide

Intervention Type COMBINATION_PRODUCT

Salicylic Acid

Salicylic Acid

Intervention Type DRUG

Hydréane légère

moisturizer

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male and/or female subjects aged 16 to 35 years
2. Subjects presenting with mild to moderate acne (stage 2 or stage 3 with at least 12 inflammatory lesions on face according to the Global Acne Evaluation)
3. Female subjects of child-bearing potential who:

* use the same reliable hormonal contraceptive method (oral contraceptive, implant, intra-uterine device, patch, cervical cap, vaginal ring and injection) for at least 3 months prior to study inclusion and throughout the study or
* use a reliable non-hormonal contraceptive method (copper intra-uterine device, condoms, diaphragm, cervical cap and spermicide) for at least 1 month prior to study inclusion and throughout the study or
* have no sexual intercourse and agreeing not to have any throughout the study or
* are surgically sterile (oophorectomy, hysterectomy or tubal ligation),
4. Subjects and/or all legal representatives (for minor subjects) who have given written informed consent
5. Subjects who are willing to comply with the study requirements
6. Subjects with Social Security (health insurance) coverage (according to the French requirements)

Exclusion Criteria

1. Subjects with any systemic disorder or face dermatoses other than acne that would in any way confound interpretation of the study results (e.g. atopic dermatitis, eczema, or psoriasis)
2. Subjects with a condition or receiving a medication and/or with a history of medical/surgical events which, in the opinion of the Investigator, could compromise the safety of the subject or affect the outcome of the study
3. Subjects with a history of skin cancer
4. Female subjects who are pregnant (positive urine pregnancy test) or lactating or who are planning to become pregnant during the study
5. Subjects who have started, stopped or changed of hormonal treatment (contraception, thyroid …) in the 3 months prior the study inclusion
6. Subjects with hypersensitivity to the active substances of Epiduo (Adapalene and/or benzoyl peroxide) or to one of its excipients
7. Subjects who are sensitive to peroxides (oxygenated water)
8. Subjects who have received isotretinoin treatment in the 6 months prior to study inclusion
9. Subjects who have been exposed to excessive UV light (natural or artificial) in the 1 month prior to the study inclusion or having planned excessive UV light exposure during the study (e.g. ski holidays, holidays in the tropics…)
10. Subjects who have used systemic drugs for more than 3 consecutive days related to antibiotics, anti-inflammatory, corticoids, anti-acneic in the 4 weeks prior to study inclusion
11. Subjects who have used topical drugs for more than 3 consecutive days related to antibiotics, anti-inflammatory, corticoids, anti-acneic in the 2 weeks prior to study inclusion
12. Subjects who have used scrub, anti-seborrheic topical cosmetic products and/or who have applied self-tanning products on face in the 1 week prior the study inclusion
13. Subjects who have applied cosmetic products for more than 5 consecutive days with alpha hydroxyl-acids, vitamin C, hyaluronic acids in the 1 week prior the study inclusion
14. Subjects having washed the face and/or the hair the day of the study inclusion (only water is accepted the morning of the study inclusion)
15. Subjects having applied any topical products on face (including make-up) the day of the study inclusion
16. Subjects who have planned a major surgery during the study requiring hospitalization under general anesthesia and the use of systemic or topical drugs (e.g. antibiotics, anti-inflammatory) for more than 1 week
17. Subjects who declare to be deprived of their freedom by administrative or legal decision or who are under guardianship
18. Subjects who cannot be contacted by telephone in case of emergency
19. Subjects belonging to the staff of the study centre
20. Subjects in an exclusion period or participating in another biomedical research study
Minimum Eligible Age

16 Years

Maximum Eligible Age

35 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Vichy Laboratoires

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

INTERTEK

Paris, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

References

Explore related publications, articles, or registry entries linked to this study.

Bouloc A, Roo E, Imko-Walczuk B, Moga A, Chadoutaud B, Dreno B. A skincare combined with combination of adapalene and benzoyl peroxide provides a significant adjunctive efficacy and local tolerance benefit in adult women with mild acne. J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1727-1731. doi: 10.1111/jdv.14379. Epub 2017 Jul 7.

Reference Type RESULT
PMID: 28573779 (View on PubMed)

Muguet Guenot L, Vourc'h Jourdain M, Saint-Jean M, Corvec S, Gaultier A, Khammari A, Le Moigne M, Boisrobert A, Paugam C, Dreno B. Confocal microscopy in adult women with acne. Int J Dermatol. 2018 Mar;57(3):278-283. doi: 10.1111/ijd.13910. Epub 2018 Jan 25.

Reference Type RESULT
PMID: 29369333 (View on PubMed)

Gollnick HP, Bettoli V, Lambert J, Araviiskaia E, Binic I, Dessinioti C, Galadari I, Ganceviciene R, Ilter N, Kaegi M, Kemeny L, Lopez-Estebaranz JL, Massa A, Oprica C, Sinclair W, Szepietowski JC, Dreno B. A consensus-based practical and daily guide for the treatment of acne patients. J Eur Acad Dermatol Venereol. 2016 Sep;30(9):1480-90. doi: 10.1111/jdv.13675. Epub 2016 May 14.

Reference Type RESULT
PMID: 27177989 (View on PubMed)

Nast A, Dreno B, Bettoli V, Bukvic Mokos Z, Degitz K, Dressler C, Finlay AY, Haedersdal M, Lambert J, Layton A, Lomholt HB, Lopez-Estebaranz JL, Ochsendorf F, Oprica C, Rosumeck S, Simonart T, Werner RN, Gollnick H. European evidence-based (S3) guideline for the treatment of acne - update 2016 - short version. J Eur Acad Dermatol Venereol. 2016 Aug;30(8):1261-8. doi: 10.1111/jdv.13776. No abstract available.

Reference Type RESULT
PMID: 27514932 (View on PubMed)

Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, Bowe WP, Graber EM, Harper JC, Kang S, Keri JE, Leyden JJ, Reynolds RV, Silverberg NB, Stein Gold LF, Tollefson MM, Weiss JS, Dolan NC, Sagan AA, Stern M, Boyer KM, Bhushan R. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016 May;74(5):945-73.e33. doi: 10.1016/j.jaad.2015.12.037. Epub 2016 Feb 17.

Reference Type RESULT
PMID: 26897386 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2018-A02481-54

Identifier Type: OTHER

Identifier Source: secondary_id

VCA 18-01

Identifier Type: -

Identifier Source: org_study_id